Need to set a new target of 0 billion for India’s bioeconomy: Kiran Mazumdar-Shaw, ET HealthWorld

Need to set a new target of $200 billion for India’s bioeconomy: Kiran Mazumdar-Shaw, ET HealthWorld

New Delhi: India is on the cusp of a major breakthrough when it comes to scaling up this enormous bioeconomy. New opportunities in the era of synthetic biology, gene editing, personalised medicine, precision medicine, and digital healthcare, which is now getting into this very exciting realm of digital prognostics and predictive diagnostics, said Kiran Mazumdar-Shaw,…

Read More
NSCLC: Advances in Treatment

NSCLC: Advances in Treatment

Doctors once thought non-small-cell lung cancer (NSCLC) was one disease. Most people got the same treatment — chemotherapy (chemo) — especially if their cancer had spread to other parts of the body.  Now, doctors know there are many different types of NSCLC, with “more coming down the pike,” says Nathan Pennell, MD, a medical oncologist…

Read More
AstraZeneca, AI biologics firm Absci tie up on cancer drug, Health News, ET HealthWorld

AstraZeneca, AI biologics firm Absci tie up on cancer drug, Health News, ET HealthWorld

Bengaluru : Anglo-Swedish drugmaker AstraZeneca has signed a deal worth up to $247 million with U.S. artificial intelligence (AI) biologics firm Absci to design an antibody to fight cancer, the Financial Times reported on Sunday. The collaboration aims to harness Absci’s AI technology for large-scale protein analysis to find a viable oncology therapy, a leading…

Read More